Steven Lichtman

Stock Analyst at Oppenheimer

(4.27)
# 455
Out of 4,712 analysts
67
Total ratings
48.94%
Success rate
19.32%
Average return

Stocks Rated by Steven Lichtman

DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $115$105
Current: $78.00
Upside: +34.62%
Zimmer Biomet Holdings
Oct 15, 2024
Maintains: Outperform
Price Target: $145$135
Current: $105.40
Upside: +28.08%
MannKind
Aug 28, 2024
Maintains: Outperform
Price Target: $10$12
Current: $6.52
Upside: +84.05%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $103$110
Current: $84.75
Upside: +29.79%
Medtronic
Aug 21, 2024
Maintains: Perform
Price Target: $92$94
Current: $79.61
Upside: +18.08%
RxSight
Aug 6, 2024
Maintains: Outperform
Price Target: $72$65
Current: $33.81
Upside: +92.25%
Tandem Diabetes Care
Jun 10, 2024
Maintains: Outperform
Price Target: $47$58
Current: $36.87
Upside: +57.31%
BrainsWay
May 9, 2024
Maintains: Outperform
Price Target: $10$11
Current: $9.22
Upside: +19.31%
AngioDynamics
Apr 5, 2024
Upgrades: Outperform
Price Target: $12
Current: $9.05
Upside: +32.60%
Merit Medical Systems
Feb 29, 2024
Maintains: Outperform
Price Target: $82$87
Current: $96.50
Upside: -9.84%
Maintains: Perform
Price Target: $58$68
Current: $89.68
Upside: -24.17%
Reiterates: Outperform
Price Target: $3.5
Current: $1.39
Upside: +151.80%
Upgrades: Outperform
Price Target: $300$275
Current: $263.36
Upside: +4.42%
Maintains: Perform
Price Target: $273$288
Current: $362.26
Upside: -20.50%
Downgrades: Perform
Price Target: $105
Current: $149.51
Upside: -29.77%
Initiates: Perform
Price Target: $150
Current: $24.08
Upside: +522.92%
Maintains: Perform
Price Target: $83$85
Current: $91.43
Upside: -7.03%
Downgrades: Perform
Price Target: n/a
Current: $0.82
Upside: -